



Working regionally to improve cancer services

SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT

HEAD AND NECK CANCER 2021 – 2022 Quality Performance Indicators (QPI) Comparative Report

Mr J Morrison, NHS Lothian, SCAN Group Chair Mr E Carr, NHS Borders Ms M Botma, NHS Dumfries & Galloway Mr J Yeo, NHS Fife Dr J Mackenzie, Clinical Oncologist, NHS Lothian

Fiona Gardiner SCAN Head and Neck Cancer Audit Facilitator

Campbell Wallis, Cancer Audit Facilitator, NHS Dumfries & Galloway Martin Keith, Cancer Improvement, NHS Dumfries & Galloway Jennifer Bruce, Senior Analyst, NHS Dumfries & Galloway Mimi Bjelogrlic, Cancer Audit Facilitator, NHS Fife

SCAN Report Index Number: SA HN01/23

HEAD AND NECK CANCER 2021-22 COMPARATIVE AUDIT REPORT

Patients diagnosed 1 April 2021 – 31 March 2022

Contents

| DOCUMENT HISTORY | 3 |
|------------------------------------------------------------------------------------|----|
| Comment by Chair of the SCAN Head and Neck Group | 3 |
| ACTION POINTS | 5 |
| Introduction and Methods | 8 |
| Dataset and Definitions | 9 |
| Data Quality | |
| Estimated Case Ascertainment | |
| Actions for Improvement | |
| DIAGNOSIS AND STAGING | |
| QPI 1: Pathological Diagnosis of Head and Neck Cancer | |
| QPI 2: Imaging Specification (i) | |
| QPI 2: Imaging Specification (ii) | 14 |
| QPI 3: Multi-disciplinary Team Meeting (MDT) | 17 |
| TREATMENT | 19 |
| QPI 4: Smoking Cessation | 19 |
| QPI 5: Oral and Dental Rehabilitation Plan Specification (i) | 21 |
| QPI 5: Oral and Dental Rehabilitation Plan Specification (ii) | 23 |
| QPI 6(i): Nutritional Screening | |
| QPI 6(ii): Nutritional Screening | 27 |
| QPI 6(iii): Nutritional Screening | 28 |
| QPI 7: Specialist Speech and Language Therapist Access | |
| QPI 8: Surgical Margins | |
| TREATMENT OUTCOMES | |
| QPI 11a: Mortality (Surgery) – Reported by Hospital of Surgery | |
| 30 day Mortality (surgery) | |
| 90 day Mortality (Surgery) | |
| QPI 11b: Mortality after Radiotherapy – Reported by Hospital of Diagnosis | 35 |
| 30 day Mortality (Radiotherapy) | 35 |
| 90 day Mortality (Radiotherapy) | |
| QPI 11c: Mortality Following Chemoradiotherapy – Reported by Hospital of Diagnosis | |
| 30 day mortality (Chemoradiotherapy) | |
| 90 day mortality (Chemoradiotherapy) | |
| QPI 12: Clinical Trials | |
| QPI 14: Time from Surgery to Adjuvant Radiotherapy/Chemotherapy | |
| QPI 15: PD-L1 Combined Proportion Score (CPS) for Decision Making | 41 |
| KEY CATEGORIES | |
| QPI Attainment Summary Years 4-6 | 46 |

DOCUMENT HISTORY

| Version | Circulation | Date | Comments |
|---------------|------------------------------------------|------------|----------------------------------------------------------------------------|
| Version 1 | Lead Clinicians' Sign off Group | 26/09/2022 | Circulated in advance of the Leads meeting |
| Version 2 | SCAN Head and Neck Lead Clinicians | 07/02/2023 | Action points and Lead Clinician's comments added |
| Version3 | SCAN Head and Neck Group | 07/02/2023 | For final comment from SCAN Group (Chairs clinical commentary to be added) |
| Final Version | SCAN Audit Reporting Framework | 14/03/2023 | For circulation to SCAN Group and Clinical Governance Group |
| Web Version | | 14/03/2023 | |

Comment by Chair of the SCAN Head and Neck Group

The healthcare environment continues to be very challenging in the wake of the covid-19 pandemic. Despite this, the SCAN H&N cancer team are managing to sustain a high quality service which continues to make incremental improvements in performance as demonstrated in this year's QPIs. A formal review of the QPIs was completed in November 2021. This is the first year of reporting since the implementation of changes following the formal review.

The diagnostic pathway for H&N cancer patients continues to perform strongly. This is despite significant pressure on radiology and pathology services.

While superficially the smoking cessation QPI 4 continues to be challenging, there were some patients who had already stopped smoking between referral and being seen in secondary care. Understandably, they were not referred to smoking cessation services but are included in the figures. Exclusion of those patients alone would markedly improve the performance to beyond 90%.

QPI 5 (oral and dental rehab) and QPI 6 (nutritional screening) continue to be beset by persistent recording difficulties.

There has been a significant and positive change in the recording mechanism for QPI 5 which is expected to result in an improvement in the performance moving forward.

QPI 6 continues to pose challenges around data collection across health boards and MDTs. Patients from SCAN affiliated health boards can be treated by WoSCAN and NCA MDTs. This results in data which is often not collected or visible to the audit team in SCAN. This can have a significantly adverse impact on the percentage performance despite the relatively small numbers involved.

There has been a notable and welcomed improvement in the performance of speech and language therapy QPI 7. This follows on from the successful bid for additional funding and the resultant recruitment of another SLT colleague. Further improvements are expected in next year's performance after collaborative regional working with NHS Borders was agreed and implemented.

The rates of 30 and 90 day mortality remain very low for both surgery and oncology. They are both well below the target of <5%.

The clinical trials QPI continues to perform well with a total of 28% patients recruited to clinical trials. This is well above the target of 15%.

There has been encouraging performance in the new QPIs 14 (Time to adjuvant radiotherapy) and 15 (PD-L1 CPS). This is the first year of reporting these new QPIs.

QPI 14 was marginally failed across SCAN and QPI 15 was passed at the first attempt.

The failure of QPI 14 was due to an under-performance in NHS Fife. This may, in part, be due to recording issues due to patients being treated in NCA area but being reported within the SCAN dataset. The audit team will continue to review their data collection processes to ensure maximum data collection across cancer network boundaries.

In summary, the SCAN H&N team continue to provide a high standard of care in what remains a very challenging environment. The overall performance in the QPIs has continued to improve over recent years. There has been significant improvement in the SLT QPI 7 with more anticipated in the coming year. The challenge posed by the introduction of two new QPIs has been met robustly by the team and I am sure the results will only continue to improve in the coming years.

Mr James Morrison Chair SCAN Head and Neck Cancer Group February 2022

ACTION POINTS

QPI Action Plans from 2021-22

| QPI | Action required | Person Responsible | Date for update |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|-------------------------|
| 6i | Patient's pathways in which screening was not performed to examined, and efforts to be made to assess similar patients in future. Fife team to record MUST on local TrakCare System. | Karen Angel/Katie Cunningham (Lothian/Fife) | Next SCAN group meeting |
| 6i | Tayside MDT to record MUST score on the MDT proforma so the auditor in Fife has this information. | Katie Cunningham (Fife) | Next SCAN group meeting |
| 6ii | Decision for not referring a patient to dietetics due to a palliative/BSC pathway should be documented. | All Clinical Staff/Dietetics | Next SCAN group meeting |
| 6iii | Issue in Lothian with surgical patients attending St John's not being referred to dietetics to be addressed | Karen Angel (Lothian) | Next SCAN group meeting |

QPI Action Points from 2020-21.

| QPI | Action required | Progress/Action Status | Status |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|--------|
| QPI 4 | Improvements noted year on year in Lothian and Borders, and will also improve next year with the QPI amendment following formal review. The possibility of a smoking cessation referral letter appearing on Trak is still however to be explored | QPI has been revised and this alone may improve performance. No action required due to QPI revision. | 3 |
| QPI 5i | Audit and Dental staff in Lothian to implement change in recording process to ensure decision for/not for dental assessment is recorded. | Dental team are now circulating a further list of patients for/not for dental assessment, shortly after each MDM. | 1 |
| QPI 6 | This QPIs results continue to improve year on year. Fife patients not attending their first MDT discussion in Lothian noted to generally miss screening. Fife lead to be made aware | Actioned | 1 |

| Head and Neck QPI Attainment Summary 2021-22 | arget% | Во | rders | | D& | G | | Fife | 9 | | Lo | thian | | sc | AN | |
|---------------------------------------------------------------------|--------|--------|----------|-------|--------|----------|-------|--------|----------|-------|--------|------------|-------|--------|------------|-------|
| QPI 1 Pathological Diagnosis of Head and Neck Cancer | 95 | N D | 19 19 | 100% | N D | 37 38 | 97.4% | N D | 63 63 | 100% | N D | 163 166 | 98.2% | N D | 282 286 | 98.6% |
| QPI 2(i) Imaging | 95 | N D | 19 19 | 100% | N D | 34 37 | 91.9% | N D | 61 63 | 96.8% | N D | 156 160 | 97.5% | N D | 270 279 | 96.8% |
| QPI 2(ii) Imaging | 95 | N D | 18 19 | 94.7% | N D | 33 34 | 97.1% | N D | 61 61 | 100% | N D | 156 156 | 100% | N D | 268 270 | 99.3% |
| QPI 3 Multi-disciplinary Team Meeting (MDT) | 95 | N D | 20 20 | 100% | N D | 36 37 | 97.3% | N D | 62 63 | 98.4% | N D | 165 168 | 98.8% | N D | 283 288 | 98.3% |
| QPI 4 Smoking Cessation | 95 | N D | 5 5 | 100% | N D | 10 10 | 100% | N D | 12 16 | 75.0% | N D | 45 59 | 76.3% | N D | 72 90 | 80.0% |
| QPI 5(i) Oral and Dental Rehabilitation Plan | 95 | N D | 7 11 | 63.6% | N D | 21 26 | 80.8% | N D | 40 44 | 90.9% | N D | 86 114 | 75.4% | N D | 154 195 | 79.0% |
| QPI 5(ii) Oral and Dental Rehabilitation Plan | 95 | N D | 7 7 | 100% | N D | 16 18 | 88.9% | N D | 29 30 | 96.7% | N D | 62 71 | 87.3% | N D | 114 126 | 90.5% |
| QPI 6(i) Nutritional Screening | 95 | N D | 18 20 | 90.0% | N D | 33 38 | 86.8% | N D | 46 64 | 71.9% | N D | 163 175 | 93.1% | N D | 260 297 | 87.5% |
| QPI 6(ii) Nutritional Screening | 90 | N D | 4 | 100% | N D | 7 7 | 100% | N D | 4 6 | 66.7% | N D | 48 55 | 87.3% | N D | 63 72 | 87.5% |
| QPI 6(iii) Nutritional Screening | 90 | N D | 9 10 | 90.0% | N D | 20 24 | 83.3% | N D | 42 44 | 95.5% | N D | 93 107 | 86.9% | N D | 164 185 | 88.6% |
| QPI 7 Specialist Speech and Language Therapist Access | 90 | N D | 4 10 | 40.0% | N D | 19 24 | 79.2% | N D | 43 45 | 95.6% | N D | 90 103 | 87.4% | N D | 159 186 | 85.5% |
| QPI 8 Surgical Margins - presented by hospital of surgery | <10 | N D | 0 0 | N/A | N D | 0 0 | N/A | N D | 0 0 | N/A | N D | 4 44 | 9.1% | N D | 4 44 | 9.1% |
| QPI 11a 30 Day Mortality (surgery) presented by hospital of surgery | <5 | N D | 0 0 | N/A | N D | 0 0 | N/A | N D | 0 0 | N/A | N D | 1 67 | 1.5% | N D | 1 67 | 1.5% |
| QPI 11a 90 Day Mortality (surgery) presented by hospital of surgery | <5 | N D | 0 0 | N/A | N D | 0 0 | N/A | N D | 0 0 | N/A | N D | 1 65 | 1.5% | N D | 1 65 | 1.5% |
| QPI 11b 30 Day Mortality (radiotherapy) | <5 | N D | 0 1 | 0.0% | N D | 0 4 | 0.0% | N D | 0 10 | 0.0% | N D | 0 27 | 0.0% | N D | 0 42 | 0.0% |

| Head and Neck QPI Attainment Summary 2021-22 Targ | et% | Bor | rders | | D& | G | | Fife |) | | Lot | thian | | sc | AN | |
|-----------------------------------------------------------------------------------------------------------------------|-----|--------|---------|-------|--------|----------|-------|--------|----------|-------|--------|-----------|-------|--------|-----------|-------|
| QPI 11b 90 Day Mortality (radiotherapy) | <5 | N D | 0 1 | 0.0% | N D | 0 3 | 0.0% | N D | 0 7 | 0.0% | N D | 0 23 | 0.0% | N D | 0 34 | 0.0% |
| QPI 11c 30 Day Mortality (chemoradiotherapy) | <5 | N D | 0 4 | 0.0% | N D | 0 12 | 0.0% | N D | 0 18 | 0.0% | N D | 0 31 | 0.0% | N D | 0 65 | 0.0% |
| QPI 11c 90 Day Mortality (chemoradiotherapy) | <5 | N D | 0 4 | 0.0% | N D | 0 9 | 0.0% | N D | 0 13 | 0.0% | N D | 0 29 | 0.0% | N D | 0 55 | 0.0% |
| Clinical Trial QPI NB: N = patients consented to Trials and on SCRN database, D = 5 year average Cancer Registry Data | 15 | N D | 8 21 | 38.1% | N D | 14 38 | 36.8% | N D | 15 71 | 21.1% | N D | 56 202 | 27.7% | N D | 93 332 | 28.0% |
| QPI 14 Time from Surgery to Adjuvant Radiotherapy/Chemotherapy | 50 | N D | 1 1 | 100% | N D | 1 1 | 100% | N D | 1 7 | 14.3% | N D | 7 14 | 50.0% | N D | 10 23 | 43.5% |
| QPI 15 PD-L1 Combined Proportion Score (CPS) | 75 | N D | 1 | 100% | N D | 1 1 | 100% | N D | 0 | 0.0% | N D | 7 9 | 77.8% | N D | 9 12 | 75.0% |

N = Numerator, D = Denominator, % = % Performance

Introduction and Methods

Cohort and Personnel

This report presents comparative data on patients newly diagnosed with Head and Neck cancer in South East Scotland Cancer Network (SCAN) at the following hospitals: Borders General Hospital (NHS Borders), Dumfries and Galloway Royal Infirmary (NHS Dumfries & Galloway), Victoria Hospital, Kirkcaldy (NHS Fife), St John's Hospital, Livingstone (NHS Lothian), New Royal Infirmary, Edinburgh (NHS Lothian), Lauriston Buildings, Edinburgh (NHS Lothian) and Western General Hospital, Edinburgh (NHS Lothian). The report covers data on patients newly-diagnosed in the twelve months from 1 April 2021 to 31 March 2022.

Lead Clinicians and staff involved in audit were as follows

| SCAN Region Hospital | | Lead Clinician | Audit Support | | |
|----------------------------------------------------|--------------------------------------------------------------------------------|---------------------|-----------------------------------|--|--|
| NHS Borders Borders General Hospital | | Mr Esmond Carr | Fiona Gardiner | | |
| NHS Dumfries & Galloway | Dumfries & Galloway Royal Infirmary | Ms Marissa Botma | Campbell Wallis Jennifer Bruce | | |
| NHS Fife Queen Margaret Hospital Victoria Hospital | | Mr Justin Yeo | Mimi Bjelogrlic | | |
| NHS Lothian & | Royal Infirmary of Edinburgh Western General Hospital St John's Hospital | Mr James Morrison | Fiona Gardiner | | |
| SCAN | Edinburgh Cancer Centre | Dr Joanna Mackenzie | - Floria Galdiner | | |

Audit Processes and data recording

Data was analysed by the audit facilitators in each NHS Board according to the measurability document provided by Public Health Scotland (PHS). SCAN data was collated by Fiona Gardiner, SCAN Audit Facilitator for Head and Neck cancer.

Data capture is focused round the process for the weekly multidisciplinary meetings i.e. ensuring that data covering patient referral, investigation, and diagnosis is being picked up through the routine process.

Surgical and Oncology data is obtained either from the clinical records (electronic systems and case notes) or by download from the Department of Clinical Oncology database within the Edinburgh Cancer Centre (ECC).

Radiotherapy is provided centrally in Edinburgh Cancer Centre. Patients living closer to either Carlisle or Dundee may opt to have treatment outwith the SCAN region. All QPIs will be analysed and presented by Hospital of Diagnosis for data verification/sign off purposes with additional reports by Hospital of Surgery as appropriate.

The process remains dependent on audit staff for capture and entry of data, and for data quality checking

All data was recorded on ECase.

Dataset and Definitions

The QPIs have been developed collaboratively with the three Regional Cancer Networks, PHS, and Healthcare Improvement Scotland. QPIs will be kept under regular review and be responsive to changes in clinical practice and emerging evidence.

The overarching aim of the cancer quality work programme is to ensure that activity at NHS board level is focussed on areas most important in terms of improving survival and patient experience whilst reducing variance and ensuring safe, effective and person-centred cancer care.

Following a period of development, public engagement and finalisation, each set of QPIs is published by Healthcare Improvement Scotland.

Accompanying datasets and measurability criteria for QPIs are published on the PHS website. NHS boards are required to report against QPIs as part of a mandatory, publicly reported, programme at a national level.

The QPI dataset for Head and Neck was implemented from 01/04/2017. Following Year 3 results the QPIs were subject to a formal review and revised documents for data collection were published in July 2018. Some of the revisions following formal review were not implemented until Year 5 (2018/19), depending on whether new data items were required or not. Accordingly QPIs 2 (spec ii), 4 and 5 (spec i and ii) were not reported in Year 4.

Following Year 6 results the QPIs were again subject to a formal review and revised documents for data collection were published in Nov 2021. The revisions following formal review were not implemented until Year 8 (2021/22). QPIs 9 and 10 were archived, and QPIs 13, 14 and 15 added.

The standard QPI format is shown below:

| QPI Title: | Short title of Quality | Short title of Quality Performance Indicator (for use in reports etc.) | | | | | | | | |
|-------------------------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|--|
| Description: | Full and clear desc | ription of the Quality Performance Indicator. | | | | | | | | |
| Rationale and Evidence: | Description of the e | evidence base and rationale which underpins this indicator. | | | | | | | | |
| | Numerator: | Of all the patients included in the denominator those who meet the criteria set out in the indicator. | | | | | | | | |
| | Denominator: | All patients to be included in the measurement of this indicator. | | | | | | | | |
| Specifications: | Exclusions: | Patients who should be excluded from measurement of this indicator. | | | | | | | | |
| | Not recorded for numerator: | Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target. | | | | | | | | |
| | Not recorded for exclusion: | Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. | | | | | | | | |
| | Not recorded for denominator: | Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard. | | | | | | | | |
| Target: | Statement of the le | vel of performance to be achieved. | | | | | | | | |

Data Quality

Clinical Sign-Off: This report compares data from reports prepared for individual hospitals and signed off as accurate following review by the lead clinicians from each service. Additionally, the collated SCAN results are reviewed jointly by the lead clinicians, including the lead Oncologist, to assess variances and provide comments on results.

External QA: SCAN Audit participates in external quality assurance (QA) of data by PHS, (i.e. when a sample of data is compared with the data definitions). A QA of the QPI Head and Neck dataset took place for Year 1 data and performance was well above the PHS minimum requirement and Scotland average.

Most patients are identified through weekly multidisciplinary meetings. The following sources are used to check for additional patients:

- 1. Pathology records
- 2. GRO Death lists
- 3. ACaDMe (Acute, Cancer, Deaths and Mental Health); a data mart part of NHS National Services Scotland.

Estimated Case Ascertainment

An estimate of case ascertainment (the percentage of the population with head and neck cancer recorded in the audit) is made by comparison with the most recent Scottish Cancer Registry five year average data from 2016 to 2020. High levels of case ascertainment provide confidence in the completeness of the audit recording and contribute to the reliability of results presented. Levels greater than 100% may be attributable to an increase in incidence. Allowance should be made when reviewing results where numbers are small and variation may be due to chance.

Number of cases recorded in audit: patients diagnosed 01.04.2021 to 31.03.2022

Estimate of case ascertainment: calculated using the average of the most recent available five years of Cancer Registry Data

| | Borders | D&G | Fife | Lothian | SCAN |
|--------------------------------|---------|--------|-------|---------|-------|
| Cases from Audit | 20 | 38 | 64 | 175 | 297 |
| Cancer Registry 5 Year Average | 21 | 38 | 71 | 202 | 332 |
| Case Ascertainment % | 95.2% | 100.0% | 90.1% | 86.6% | 89.5% |

Source: Scottish Cancer Registry, PHS. Data extracted from ACaDMe on 15/08/2022. Death certificate only cases have been excluded. Cases that have been diagnosed in the private sector but received any treatment in NHS hospitals have been included.

Actions for Improvement

After final sign off, the process is for the report to be sent to the Clinical Governance groups within the four health boards and to the Regional Cancer Planning Group. Action plans and progress with plans will be highlighted to the groups. The report will be placed on the SCAN website once it has been fully signed-off and checked for any disclosive material.

Fiona Gardiner SCAN Audit Facilitator

DIAGNOSIS AND STAGING

QPI 1: Pathological Diagnosis of Head and Neck Cancer Target = 95%

Numerator = Number of patients with head and neck cancer who have a cytological or histological diagnosis before treatment.


Denominator = All patients with head and neck cancer.

Exclusions = (a) Patients who die before first treatment (b) Patients who decline treatment.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|--------------------------------|---------|-------|--------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 1 | 0 | 1 | 9 | 11 |
| Numerator | 19 | 37 | 63 | 163 | 282 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 19 | 38 | 63 | 166 | 286 |
| Not Recorded for Exclusion | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 97.4% | 100.0% | 98.2% | 98.6% |

Comments:

The target was met by all Boards



Some patients within this cohort were discussed and treated outwith SCAN (but were diagnosed in SCAN and are therefore SCAN patients). So as to focus only on patients discussed and treated within SCAN, a second table will appear within each QPI which omits these patients. This year 13 Dumfries patients were discussed at MDTs in WoSCAN

(Glasgow) and 22 Fife patients were discussed at MDT in NOSCAN (Tayside). Additionally 1 Fife patient was not discussed at MDT but what also treated in NOSCAN.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|--------------------------------|---------|-------|--------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 1 | 0 | 0 | 9 | 11 |
| | ı | | | | |
| Numerator | 19 | 24 | 41 | 163 | 247 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 19 | 25 | 41 | 166 | 251 |
| | ı | | | | |
| Not Recorded for Exclusion | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 96.0% | 100.0% | 98.2% | 98.4% |

QPI 2: Imaging Specification (i) Target = 95%

Numerator = Number of patients with head and neck cancer who undergo CT and/or MRI of the primary site and draining lymph nodes with CT of the chest before the initiation of treatment.

Denominator = All patients with head and neck cancer.

Exclusions = (a) Patients who undergo diagnostic excision biopsy as the definitive surgery (b) Patients who die before first treatment (c) Patients who decline treatment.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 1 | 1 | 1 | 15 | 18 |
| | | | | | |
| Numerator | 19 | 34 | 61 | 156 | 270 |
| Not Recorded for Numerator | 0 | 0 | 0 | 1 | 1 |
| Denominator | 19 | 37 | 63 | 160 | 279 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 91.9% | 96.8% | 97.5% | 96.8% |

Comments where the QPI was not met:


D&G: The target was not met showing a shortfall of 3.1% (3 cases). For these 3 patients, 1 was frail and not fit for treatment/scanning, 1 did not have a CT of the neck performed and was for Best Supportive Care (BSC), and 1 patient had a diagnosis by incidental finding; they discussed in WoSCAN and a decision made that no scans were needed.

Removal of this WoSCAN discussed patient brings the % performance in this QPI up to 94.4% in D&G.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|--------------------------------|---------|-------|--------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 1 | 0 | 0 | 15 | 16 |
| | ı | | | | |
| Numerator | 19 | 23 | 39 | 156 | 237 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 19 | 25 | 41 | 160 | 245 |
| | | | | | |
| Not Recorded for Exclusion | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 92.0% | 100.0% | 97.5% | 96.7% |

QPI 2i: Imaging Head and Neck Cancer 2017/18 to 2021/22

Action: None identified



QPI 2: Imaging Specification (ii) Target = 95%

Numerator = Number of patients with head and neck cancer who undergo CT and/or MRI of the primary site and draining lymph nodes with CT of the chest before the initiation of treatment where the report is available within 2 weeks of the final imaging procedure.

Denominator = All patients with head and neck cancer who undergo CT and/or MRI of the primary site and draining lymph nodes with CT of the chest before initiation of treatment.

Exclusions = (a) Patients who undergo diagnostic excision biopsy as the definitive surgery (b) Patients who die before first treatment (c) Patients who decline treatment.


| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|--------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 1 | 4 | 3 | 19 | 27 |
| Numerator | 18 | 33 | 61 | 156 | 268 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 19 | 34 | 61 | 156 | 270 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 1 | 1 |
| % Performance | 94.7% | 97.1% | 100.0% | 100.0% | 99.3% |


Comments where the QPI was not met:

Borders: The target was not met showing a shortfall of 0.3% (1 case). For this one patient reporting took 20 days. This period was also noted to fall over the festive period.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|--------------------------------|---------|--------|--------|---------|---------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 1 | 0 | 0 | 19 | 20 |
| | ı | | | | |
| Numerator | 18 | 25 | 41 | 156 | 240 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 19 | 25 | 41 | 156 | 241 |
| | | | | | |
| Not Recorded for Exclusion | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 94.7% | 100.0% | 100.0% | 100.0% | 99.1.7% |

Action: None identified





QPI 2(ii) was not reported in Year 4 (2017/18) due to first formal review changes.

QPI 3: Multi-disciplinary Team Meeting (MDT) Target = 95%

Numerator = Number of patient with head and neck cancer discussed at the MDT before definitive treatment.

Denominator = All patients with head and neck cancer.

Exclusions = Patients who die before first treatment or who undergo diagnostic excision biopsy as the definitive surgery.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|----------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 0 | 1 | 1 | 8 | 10 |
| | | | | | |
| Numerator | 20 | 36 | 62 | 165 | 283 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 20 | 37 | 63 | 167 | 287 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for the Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 97.3% | 98.4% | 98.8% | 98.6% |


Comments:

The target was met by all Boards

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|----------------------------------|---------|-------|--------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 0 | 0 | 1 | 8 | 9 |
| | 1 | | | | |
| Numerator | 20 | 24 | 40 | 165 | 249 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 20 | 25 | 40 | 167 | 252 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for the Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 96.0% | 100.0% | 98.8% | 98.8% |

QPI 3: Multi-Disciplinary Team Meeting (MDT)

Head and Neck Cancer 2017/18 to 2021/22



TREATMENT

QPI 4: Smoking Cessation Target = 95%

Numerator = Number of patient with head and neck cancer who smoke who are offered referral to smoking cessation before first treatment

Denominator = All patients with head and neck cancer who smoke

Exclusions = Patients undergoing supportive care only

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|--------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 15 | 28 | 48 | 116 | 207 |
| | | | | | |
| Numerator | 5 | 10 | 12 | 45 | 72 |
| Not Recorded for Numerator | 0 | 0 | 4 | 0 | 4 |
| Denominator | 5 | 10 | 16 | 59 | 90 |
| | | ı | ı | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 2 | 0 | 1 | 3 |
| % Performance | 100.0% | 100.0% | 75.0% | 76.3% | 80.0% |

Comments where the QPI was not met:


Fife: The target was not met showing a shortfall of 20.0% (4 cases). For these 4 patients data was not recorded. They were discussed in the NOSCAN (Tayside) MDT and smoking cessation was not documented.

Lothian: The target was not met showing a shortfall of 18.7% (14 cases). For these 14 patients, 9 stopped smoking themselves between the time of first referral for investigation of potential cancer and MDT; a smoking cessation referral was therefore not offered. A further 2 patients were offered referral to smoking cessation after first treatment, 2 patients declined all interventions and treatment (referral therefore not offered), and for 1 patient referral was not offered.

On review, it is noted that removal of the 9 patients who stopped smoking themselves between time of referral into secondary care and MDT discussion would bring Lothian's performance up to 90%. Additionally results in this QPI have shown improvement year on year.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|----------------------------------|---------|--------|--------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 15 | 18 | 32 | 116 | 181 |
| | | | | | |
| Numerator | 5 | 7 | 9 | 45 | 66 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 5 | 7 | 9 | 59 | 80 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for the Denominator | 0 | 0 | 0 | 1 | 1 |
| % Performance | 100.0% | 100.0% | 100.0% | 76.3% | 82.5% |

Action: None Identified. Awaiting publication of the Healthcare Improvement Scotland (HIS) review which included this QPI.



This QPI was not reported in Year 4 (2017/18). For Year 6 reporting the QPI was also amended to allow BSC patients who are offered referral on the same day as treatment to pass this QPI. Following the second formal review during Year 7 (2020/21), an exclusion category was also added for patients undergoing BSC.

QPI 5: Oral and Dental Rehabilitation Plan Specification (i) Target = 95%

Numerator = Number of patients with head and neck cancer undergoing active treatment in whom the decision for requiring pre-treatment assessment has been made jointly by Consultants in Restorative Dentistry and the MDT

Denominator = All patients with head and neck cancer undergoing active treatment (no exclusions)

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 9 | 12 | 20 | 61 | 102 |
| | | | | | |
| Numerator | 7 | 21 | 40 | 86 | 154 |
| Not Recorded for Numerator | 4 | 5 | 4 | 28 | 41 |
| Denominator | 11 | 26 | 44 | 114 | 195 |
| | _ | • | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 1 | 0 | 1 |
| % Performance | 63.6% | 80.8% | 90.9% | 75.4% | 79.0% |

Comments where the QPI was not met:

Borders: The target was not met showing a shortfall of 31.4% (4 cases). For these 4 patients the decision for requiring assessment was not recorded.

D&G: The target was not met showing a shortfall of 14.2% (5 cases). For these 5 patients the decision for requiring assessment was not recorded.


Fife: The target was not met showing a shortfall of 4.1% (4 cases). For these 4 patients the decision for requiring assessment was not recorded. All patients were discussed at the Lothian MDT. A further 1 patient was not in the denominator due to treatment intent not being recorded (not recorded for the denominator).

Lothian: The target was not met showing a shortfall of 19.6% (28 cases). For these 28 patients the decision for requiring assessment was not recorded.

During the course of this cohort year, a change in the recording process for dental assessment decisions was made at the Lothian MDT. From February 2022 when this change was implemented, the data shows a significant improvement in recording. The full impact of this change is not seen in the above QPI results as the change was implemented partway through the cohort year. The number of 'Not Recorded for Numerator' cases is therefore expected to drop next year for all regions.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|----------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 9 | 6 | 14 | 61 | 90 |
| | | | | | |
| Numerator | 7 | 14 | 23 | 86 | 130 |
| Not Recorded for the Numerator | 4 | 5 | 4 | 28 | 41 |
| Denominator | 11 | 19 | 27 | 114 | 171 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for the Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 63.6% | 73.7% | 85.2% | 75.4% | 76.0% |

Action: None identified. Change in Lothian data recording processes expected to improve results next year.



Following the second formal review during Year 7 (2020/21), QPI 5(i) was updated and the denominator changed from all those undergoing active treatment to all those undergoing treatment with curative intent. The exclusion of patients with T1/T2/N0 larynx cancer was also removed. Additionally, this QPI was not reported in Year 4 (2017/18).

QPI 5: Oral and Dental Rehabilitation Plan Specification (ii) Target = 95%

Numerator = Number of patients with head and neck cancer who are identified as requiring pre-treatment assessment that have assessment carried out before initiation of treatment.

Denominator = All patients with head and neck cancer who are identified by all relevant members of the MDT as requiring dental assessment (no exclusions)

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 13 | 20 | 34 | 105 | 172 |
| Numerator | 7 | 16 | 29 | 62 | 114 |
| Not Recorded for Numerator | 0 | 0 | 1 | 0 | 1 |
| Denominator | 7 | 18 | 30 | 71 | 126 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 8 | 8 | 12 | 61 | 89 |
| % Performance | 100.0% | 88.9% | 96.7% | 87.3% | 90.5% |

Comments where the QPI was not met:


D&G: The target was not met showing a shortfall of 6.1% (2 cases). For these 2 patients, 1 patient was assessed after first treatment and 1 patient did not have a dental appointment and was edentulous.

Lothian: The target was not met showing a shortfall of 7.7% (9 cases). For these 9 cases who were identified as requiring a pre-treatment dental assessment but that were not seen, 5 were later noted as edentulous and did not require to be assessed. 4 patients were not assessed pre-treatment (1 patient had dental delayed and was then missed, 1 patient had complex drug misuse issues, 1 was for a WLE of the tongue and local approach was that there was no dental assessment required).

During the course of this cohort year, a change in the recording process for dental assessment decisions was made at the Lothian MDT. From February 2022 when this change was implemented the data shows a significant improvement in recording. The full impact of this change is not seen in the above QPI results as the change was implemented partway through the cohort year. The number of 'Not Recorded for Denominator' cases is therefore expected to drop next year for all regions.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|----------------------------------|---------|--------|-------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 13 | 11 | 24 | 105 | 153 |
| | | | | | |
| Numerator | 7 | 13 | 16 | 62 | 98 |
| Not Recorded for the Numerator | 0 | 0 | 1 | 0 | 1 |
| Denominator | 7 | 14 | 17 | 71 | 109 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for the Denominator | 8 | 8 | 11 | 61 | 88 |
| % Performance | 100.0% | 100.0% | 94.1% | 87.3% | 89.9% |

Action: None identified. Change in Lothian data recording processes expected to improve results next year.



Following the second formal review during Year 7 (2020/21), QPI 5(ii) was updated and the exclusion of patients with T1/T2/N0 larynx cancer was removed. Additionally, this QPI was not reported in Year 4 (2017/18).

QPI 6(i): Nutritional Screening Target = 95%

Numerator = Number of patients with head and neck cancer who undergo nutritional screening with the Malnutrition Universal Screening Tool (MUST) before first treatment.

Denominator = All patients with head and neck cancer (No exclusions)

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 0 | 0 | 0 | 0 | 0 |
| | 1 | | | | |
| Numerator | 18 | 33 | 46 | 163 | 260 |
| Not Recorded for Numerator | 0 | 0 | 13 | 0 | 13 |
| Denominator | 20 | 38 | 64 | 175 | 297 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 90.0% | 86.8% | 71.9% | 93.1% | 87.5% |

Comments where the QPI was not met:

Borders: The target was not met showing a shortfall of 5.0% (2 cases). Screening was not performed for these 2 patients.

D&G: The target was not met showing a shortfall of 8.2% (5 cases). Of these 5 patients, 2 patients were MUST screened after first treatment, 1 patient was already under the long term care of dietitians, 1 patient was referred to palliative care and 1 patient was for BSC and their GP referred them to a dietitian.

Fife: The target was not met showing a shortfall of 23.1% (18 cases). For 13 patients MUST screening was not performed. 12 of these patients were discussed in NOSCAN (Tayside) MDT and all 12 had dietetic input in Fife, 1 patient in Lothian MDT was confirmed as having dietetic input from both Lothian and Fife dietitians. For a further 5 patients screening was not performed (3 of these patients were discussed in NOSCAN (Tayside) MDT, 1 patient declined screening and died shortly after diagnosis, and 1 patient did not attend the MDT clinic).

15 out of 18 patients who do not have a recorded MUST were treated in Tayside. The majority of patients were seen by the Fife dietitian but this information has not been captured as they did not have a MUST recorded.

Lothian: The target was not met showing a shortfall of 1.9% (12 cases). Of these 12 cases, screening was not performed for 11 patients, and 1 patient declined all interventions.

| Target 95% | Borders | D&G | Fife | Lothian | SCAN |
|--------------------------------|---------|-----|------|---------|------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 0 | 0 | 0 | 0 | 0 |
| | • | | | | |
| Numerator | 18 | 24 | 38 | 163 | 243 |
| Not Recorded for the Numerator | 0 | 0 | 2 | 0 | 2 |
| Denominator | 20 | 25 | 41 | 175 | 261 |

Not for wider dissemination – assessment risk of disclosure of sensitive personal information not yet undertaken

| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
|----------------------------------|-------|-------|-------|-------|-------|
| Not Recorded for the Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 90.0% | 96.0% | 92.7% | 93.1% | 93.1% |

Action: Patient's pathways in which screening was not performed to examined, and efforts to be made to assess similar patients in future. Fife MDT to record MUST score on the MDT local TrakCare system.

QPI 6(i): Nutritional Screening

Head and Neck Cancer 2017/18 to 2021/22 100% 90% 80% Performance against QPI 70% 60% 50% 40% 30% 20% 10% 0% D&G Fife SCAN **Borders** Lothian 2017/18 81.3% 16.7% 71.2% 80.8% 73.0% 2018/19 78.6% 67.7% 86.5% 87.5% 84.2% 2019/20 75.8% 89.2% 95.0% 80.0% 94.1% 2020/21 100.0% 93.3% 81.7% 93.1% 91.2% 2021/22 90.0% 86.8% 71.9% 93.1% 87.5% Target 95% 95% 95% 95% 95%

QPI 6(ii): Nutritional Screening Target = 90%

Numerator = Number of patients with head and neck cancer at high risk of malnutrition (MUST Score or 2 or more) who are assessed by a specialist dietitian.

Denominator = All patients with head and neck cancer at high risk of malnutrition (MUST Score of 2 or more) (No exclusions).

| Target 90% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|--------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 16 | 31 | 58 | 120 | 225 |
| | 1 | | | | |
| Numerator | 4 | 7 | 4 | 48 | 63 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 4 | 7 | 6 | 55 | 72 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 1 | 13 | 0 | 0 |
| % Performance | 100.0% | 100.0% | 66.7% | 87.3% | 87.5% |

Comments where the QPI was not met:


Fife: The target was not met showing a shortfall of 23.3% (2 cases). For these 2 patients assessment did not occur but dietetic input was provided or offered to both patients. Additionally, for 13 patients a MUST score was not recorded (12 of these patients were discussed in NOSCAN (Tayside) MDT and all had dietetic input in Fife.

Lothian: The target was not met showing a shortfall of 2.7% (7 cases). Of these 7 cases, 5 were for BSC, 1 case was treated palliatively and 1 case curatively. Following review, Lothian Dietetics noted that clinical judgement was likely used and patients were likely not referred to dietetics as on a palliative/BSC pathway.

Some patients within this cohort were discussed and treated outwith SCAN. So as to focus only on patients discussed and treated within SCAN, the table below omits these patients (13 Dumfries patients discussed and treated in WoSCAN, and 23 Fife patients treated in NOSCAN).

| Target 90% | Borders | D&G | Fife | Lothian | SCAN |
|----------------------------------|---------|--------|-------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 16 | 20 | 35 | 120 | 191 |
| | | | | | |
| Numerator | 4 | 5 | 4 | 48 | 61 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 4 | 5 | 6 | 55 | 70 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for the Denominator | 0 | 1 | 1 | 0 | 0 |
| % Performance | 100.0% | 100.0% | 66.7% | 87.3% | 87.1% |

Action: Decision for not referring a patient to dietetics due to a palliative/BSC pathway should be documented.



QPI 6(iii): Nutritional Screening Target = 90%

Numerator = Number of patients with oral, pharyngeal or laryngeal cancer undergoing treatment with curative intent who are assessed by a specialist dietitian.

Denominator = All patients with oral, pharyngeal or laryngeal cancer undergoing treatment with curative intent. (No exclusions)

| Target 90% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 10 | 14 | 20 | 68 | 112 |
| | 1 | | | | |
| Numerator | 9 | 20 | 42 | 93 | 164 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 10 | 24 | 44 | 107 | 185 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 1 | 0 | 1 |
| % Performance | 90.0% | 83.3% | 95.5% | 86.9% | 88.6% |

Comments where the QPI was not met:


D&G: The target was not met showing a shortfall of 6.7% (4 cases). Of these 4 patients who were not assessed, for 2 patients dietetic input was not needed upon review (1 patient had weight monitored in OMFS follow up clinic), 1 patient declined appointments, and 1 patient had no dietetics referral sent.

Lothian: The target was not met showing a shortfall of 3.1% (14 cases). Of these 14 patients who were not assessed, 13 patients had a MUST of '0' (low risk) pre-treatment, and 1 patient had a pre-treatment MUST of '2' (high risk). Additionally, of these 14 patients, 12 were surgical patients (4 laser surgery), 1 patient was for radical radiotherapy and no dietetic referral was sent for this patient, and 1 patient was subsequently moved onto a palliative pathway.

Some patients within this cohort were discussed and treated outwith SCAN. So as to focus only on patients discussed and treated within SCAN, the table below omits these patients (13 Dumfries patients discussed and treated in WoSCAN, and 23 Fife patients treated in NOSCAN).

| Target 90% | Borders | D&G | Fife | Lothian | SCAN |
|----------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 10 | 7 | 14 | 68 | 99 |
| | 1 | | | | |
| Numerator | 9 | 17 | 25 | 93 | 144 |
| Not Recorded for the Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 10 | 18 | 27 | 107 | 162 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for the Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 90.0% | 94.4% | 92.6% | 86.9% | 88.9% |

Action: Issue in Lothian with surgical patients attending St John's not being referred to dietetics to be addressed



QPI 7: Specialist Speech and Language Therapist Access Target = 90%

Numerator = Number of patients with oral, pharyngeal or laryngeal cancer undergoing treatment with curative intent who are seen by a specialist Speech and Language Therapist before treatment.

Denominator = All patients with oral, pharyngeal or laryngeal cancer undergoing treatment with curative intent.

Exclusions = Patients who refuse assessment.

| Target 90% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 10 | 14 | 19 | 72 | 111 |
| | | ı | | | |
| Numerator | 4 | 19 | 43 | 90 | 156 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 10 | 24 | 45 | 103 | 182 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 1 | 0 | 0 |
| % Performance | 40.0% | 79.2% | 95.6% | 87.4% | 85.7% |

Comments where the QPI was not met:

Borders: The target was not met showing a shortfall of 50.0% (6 cases). Of these 6 patients, all were not seen pre-treatment by SLT.

During the course of this cohort year, provision was made for Borders patients to see Specialist Speech and Language Therapists locally in the Borders. The full impact of this change is not seen in the above QPI results as the change was implemented partway through the year. Borders QPI performance is expected therefore to improve again in the following cohort and no further action is identified for Borders.

D&G: The target was not met showing a shortfall of 10.8% (5 cases). Of these 5 patients, 2 did not require SLT intervention, 2 were seen by SLT but after treatment had started, and 1 patient was not seen by SLT.

Lothian: The target was not met showing a shortfall of 2.6% (13 cases). Of these 13 patients who were not seen by SLT prior to treatment, 9 were surgically treated patients who were not seen by SLT prior to surgery, 3 patients declined a pre-treatment appointment with SLT, and 1 patient was not seen by SLT prior to starting chemoradiotherapy treatment.

At the point of writing this report interim data for the Year 2022/23 shows Lothian's percentage performance at 92.5%

Action: None identified. Additional resources have been appointed and the impact of this will be fully assessed next year

| Target 90% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|-------|-------|---------|-------|
| 2020-21 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 10 | 7 | 12 | 72 | 101 |
| Numerator | 4 | 15 | 27 | 90 | 136 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 10 | 18 | 29 | 103 | 160 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 40.0% | 83.3% | 93.1% | 87.4% | 85.0% |

QPI 7: Specialist Speech and Language Therapist Access Head and Neck Cancer 2017/18 to 2021/22 100% 90% 80% Performance against QPI 70% 60% 50% 40% 30% 20% 10% 0% **Borders** D&G Fife Lothian **SCAN** 2017/18 40.0% 9.4% 58.8% 76.7% 55.6% 2018/19 10.0% 56.3% 10.6% 81.6% 57.8% 2019/20 0.0% 85.7% 32.4% 66.7% 57.8% 2020/21 95.7% 8.3% 80.6% 77.1% 75.3% 2021/22 40.0% 79.2% 95.6% 87.4% 85.7% Target 90% 90% 90% 90% 90%

SCAN Comparative Head and Neck QPI Report 2021/22

QPI 8: Surgical Margins Target ≤10%

Numerator = Number of patients with squamous cell carcinoma of the oral cavity, larynx or pharynx who undergo open surgical resection with curative intent with final excision margins of less than 1mm (on pathology report).

Denominator = All patients with squamous cell carcinoma of the oral cavity, larynx or pharynx who undergo open surgical resection with curative intent

Exclusions = Patients with naso-pharyngeal cancer, posterior pharyngeal wall cancer and upper oesophageal cancer.

Data presented by Hospital of Surgery


| Target <10% | Borders | D&G (New Royal Infirmary) | Fife (Victoria Hospital) | Lothian (St Johns) | SCAN |
|------------------------------|---------|---------------------------------|--------------------------------|-----------------------|------|
| Numerator | 0 | 0 | 0 | 4 | 4 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 0 | 0 | 0 | 44 | 44 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | N/A | N/A | N/A | 9.1% | 9.1% |

| % Performance in previous | Borders | D&G | Fife | Lothian | SCAN |
|---------------------------|---------|------|------|---------|-------|
| 2017/18 | N/A | N/A | N/A | 5.3% | 5.3% |
| 2018/19 | N/A | 0.0% | N/A | 4.9% | 4.8% |
| 2019/20 | N/A | 0.0% | N/A | 17.2% | 15.6% |
| 2020/21 | N/A | N/A | N/A | 8.1% | 8.1% |

Comments:

All Boards reporting data met the target. All death are reviewed at M&M meetings

QPI 8: Surgical Margins
Head and Neck Cancer 2017/18 to 2021/22



TREATMENT OUTCOMES

QPI 11a: Mortality (Surgery) – Reported by Hospital of Surgery

Target <5%

Numerator = Number of patients with head and neck cancer who undergo curative surgery who die within 30 days of treatment.

Denominator = All patients with head and neck cancer who undergo curative surgery.

Exclusions = No exclusions

30 day Mortality (surgery)

| Target <5% | Borders | D&G (New Royal Infirmary) | Fife (Victoria Hospital) | Lothian (St John's) | SCAN |
|----------------------------------------------|---------|---------------------------------|--------------------------------|------------------------|---------|
| Numerator | 0 | 0 | 0 | 1 | 1 |
| Not Recorded for Numerator Denominator | 0 | 0 | 0 | 0 67 | 0 67 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | N/A | N/A | N/A | 1.5% | 1.5% |

| % Performance in | Borders | D&G | Fife | Lothian | SCAN |
|------------------|---------|------|------|---------|------|
| 2017/18 | N/A | 0.0% | N/A | 0.0% | 0.0% |
| 2018/19 | N/A | 0.0% | N/A | 0.0% | 0.0% |
| 2019/20 | N/A | 0.0% | 0.0% | 0.0% | 0.0% |
| 2020/21 | N/A | N/A | N/A | 0.0% | 0.0% |

Comments:

All Boards reporting data met the target

90 day Mortality (Surgery)

| Target <5% | Borders | D&G (New Royal Infirmary) | Fife (Victoria Hospital) | Lothian (St John's) | SCAN |
|---------------------------------|---------|---------------------------------|--------------------------------|------------------------|------|
| Numerator | 0 | 0 | 0 | 1 | 1 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 0 | 0 | 0 | 65 | 65 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | N/A | N/A | N/A | 1.5% | 1.5% |

Lothian – 90 days since treatment not reached by 2 cases

| % Performance in | Borders | D&G | Fife | Lothian | SCAN |
|------------------|---------|------|------|---------|------|
| 2017/18 | N/A | 0.0% | N/A | 3.2% | 3.2% |
| 2018/19 | N/A | 0.0% | N/A | 0.0% | 0.0% |
| 2019/20 | N/A | 0.0% | 0.0% | 3.2% | 3.1% |
| 2020/21 | N/A | N/A | N/A | 1.6% | 1.6% |

Comments:

All Boards reporting data met the target

QPI 11b: Mortality after Radiotherapy – Reported by Hospital of Diagnosis Target <5%

Numerator = Number of patients with head and neck cancer who undergo curative radiotherapy who die within 30 days of treatment.

Denominator = All patients with head and neck cancer who undergo curative radiotherapy. (No exclusions)

30 day Mortality (Radiotherapy)

| Target <5% | Borders | D&G | Fife | Lothian | SCAN |
|---------------------------------|---------|-------|------|---------|------|
| | | | | | |
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 19 | 4 | 54 | 148 | 255 |
| Numerator | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 1 | 4 | 10 | 27 | 42 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| % Performance in previous years | | | | | |
| 2017/18 | 0.0% | 0.0% | 0.0% | 6.3% | 3.6% |
| 2018/19 | 0.0% | N/A | 0.0% | 6.3% | 4.2% |
| 2019/20 | 0.0% | 0.0% | 0.0% | 4.2% | 2.5% |
| 2020/21 | 0.0% | 33.3% | 0.0% | 0.0% | 2.1% |

Comments:

All Boards reporting data met the target

90 day Mortality (Radiotherapy)

| Target <5% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|------|------|---------|------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 19 | 34 | 54 | 152 | 259 |
| | 1 | | | | |
| Numerator | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 1 | 3 | 7 | 23 | 34 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |

D&G – 90 days since treatment not reached by 1 case Fife – 90 days since treatment not reached by 3 cases Lothian – 90 days since treatment not reached by 4 cases

| % Performance in previous years | | | | | |
|---------------------------------|------|-------|------|------|------|
| 2017/18 | 0.0% | 0.0% | 0.0% | 6.3% | 3.6% |
| 2018/19 | 0.0% | N/A | 0.0% | 6.3% | 4.3% |
| 2019/20 | N/A | 0.0% | 0.0% | 4.5% | 2.9% |
| 2020/21 | 0.0% | 33.3% | 0.0% | 6.9% | 6.5% |

Comments:

All Boards reporting data met the target

QPI 11c: Mortality Following Chemoradiotherapy – Reported by Hospital of Diagnosis Target <5%

Numerator = Number of patients with head and neck cancer who undergo curative chemoradiotherapy who die within 30 days of treatment.

Denominator = All patients with head and neck cancer who undergo curative chemoradiotherapy (No exclusions)

30 day mortality (Chemoradiotherapy)

| Target <5% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|------|------|---------|------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 16 | 26 | 46 | 144 | 232 |
| | | | | | |
| Numerator | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 4 | 12 | 18 | 31 | 65 |
| | ı | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |

⁴ patients from Fife were treated outwith SCAN in NOSCAN

| % Performance in previous years | Borders | D&G | Fife | Lothian | SCAN |
|---------------------------------|---------|------|------|---------|------|
| 2017/18 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 2018/19 | 0.0% | 0.0% | 0.0% | 1.7% | 1.1% |
| 2019/20 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 2020/21 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |

Comments:

All Boards met the target

90 day mortality (Chemoradiotherapy)

| Target <5% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|------|------|---------|------|
| 2020-21 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 16 | 26 | 46 | 146 | 234 |
| | | | | | |
| Numerator | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 4 | 9 | 13 | 29 | 55 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |

D&G – 90 days since treatment not reached by 3 cases

Fife – 90 days since treatment not reached by 5 cases

Lothian – 90 days since treatment not reached by 2 cases

| % Performance in previous years | Borders | D&G | Fife | Lothian | SCAN |
|---------------------------------|---------|------|------|---------|------|
| 2017/18 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 2018/19 | 0.0% | 0.0% | 0.0% | 3.6% | 2.3% |
| 2019/20 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| 2020/21 | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |

Comments:

All Boards met the target

QPI 12: Clinical Trials Target = 15%

Numerator = Number of patients with head and neck cancer consented for a clinical trial / research study.

Denominator = All patients with head and neck cancer (no exclusions)

Note: The clinical trials QPI is measured using SCRN data and Cancer Registry data (5 year average of case ascertainment 2016-2020)

| Target 15% | Borders | D&G | Fife | Lothian | SCAN |
|---------------|---------|-------|-------|---------|-------|
| Numerator | 8 | 14 | 15 | 56 | 93 |
| Denominator | 21 | 38 | 71 | 202 | 332 |
| % Performance | 38.1% | 36.8% | 21.1% | 27.7% | 28.0% |


| Trials in 2021 | Trial Type | Numbers Recruited |
|------------------|----------------|-------------------|
| CompARE | Interventional | 11 |
| SR1171 | Translational | 46 |
| PATHOS | Interventional | 2 |
| PETNECK2 | Interventional | 21 |
| Biobank SR1418 | Translational | 7 |
| Cell free DNA | Translational | 45 |
| SCCAMP V1.0 | Translational | 2 |
| CCP-Cancer UK | Translational | 1 |
| POPPY | Interventional | 4 |
| Revolution Study | Interventional | 1 |
| UPSTREAM | Translational | 1 |

NB: some patients recruited to multiple trials

All Boards met the target

| % Performance in previous years | Borders | D&G | Fife | Lothian | SCAN |
|---------------------------------|---------|-------|-------|---------|-------|
| 2017/18 | 16.7% | 0.0% | 4.6% | 6.3% | 5.8% |
| 2018/19 | 5.3% | 5.6% | 4.5% | 11.9% | 9.3% |
| 2019/20 | 26.3% | 20.0% | 18.8% | 19.3% | 19.7% |
| 2020/21 | 38.1% | 8.1% | 14.9% | 21.0% | 19.3% |

QPI 12: Clinical Trials
Head and Neck Cancer 2017/18 to 2021/22



QPI 14: Time from Surgery to Adjuvant Radiotherapy/Chemotherapy Target 50%

Numerator = Number of patients with squamous cell carcinoma of the oral cavity, pharynx or larynx who undergo adjuvant radiotherapy or chemoradiotherapy who commence this within 7 weeks of definitive surgical resection

Denominator = All patients with squamous cell carcinoma of the oral cavity, pharynx or larynx who undergo definitive surgical resection followed by adjuvant radiotherapy or chemoradiotherapy

Exclusions = no exclusions

| Target 50% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|--------|-------|---------|-------|
| 2021-22 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 19 | 37 | 57 | 161 | 274 |
| | 1 | | | | |
| Numerator | 1 | 1 | 1 | 7 | 10 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 1 | 1 | 7 | 14 | 23 |
| | | | | | |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 100.0% | 14.3% | 50.0% | 43.5% |


Comments where QPI not met:

Fife: The target was not met showing a shortfall of 35.7% (6 cases). These 6 patients had surgery in NOSCAN (Tayside). 3 patients had complications following initial surgery, 2 patients did not have a documented reason for delay, and 1 patient did not have their pathology available at the first oncology appointment.

Additional Comments: The 7 patients in Lothian who did not meet the target were reviewed by the Oncology team and all were unavoidable delays.

Action: None identified for SCAN.

| Target 50% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|--------|--------|---------|-------|
| 2021-22 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 19 | 24 | 40 | 161 | 244 |
| Numerator | 1 | 1 | 1 | 7 | 10 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 1 | 1 | 1 | 14 | 17 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 100.0% | 100.0% | 50.0% | 58.8% |



QPI 14: Time from Surgery to Adjuvant Radiotherapy/Chemotherapy
Head and Neck Cancer 2021/22

QPI 15: PD-L1 Combined Proportion Score (CPS) for Decision Making Target 75%

Numerator = Number of patients with squamous cell head and neck cancer undergoing first line palliative SACT for whom PD-L1 CPS is reported within 14 days of MDT request

Denominator = All patients with squamous cell head and neck cancer undergoing first line palliative SACT

Exclusions = Patients with nasopharyngeal cancer

| Target 75% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|--------|------|---------|-------|
| 2021-22 Cohort | 20 | 38 | 64 | 175 | 297 |
| Ineligible for this QPI | 19 | 37 | 63 | 166 | 285 |
| Numerator | 1 | 1 | 0 | 7 | 9 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 1 | 1 | 1 | 9 | 12 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 100.0% | 0.0% | 77.8% | 75.0% |

Comments where QPI not met:

Fife: The target was not met showing a shortfall of 75.0% (1 case). For this 1 patient PD-L1 was not requested at the Lothian MDT.

Action: None identified

| Target 75% | Borders | D&G | Fife | Lothian | SCAN |
|------------------------------|---------|--------|------|---------|-------|
| 2021-22 Cohort | 20 | 25 | 41 | 175 | 261 |
| Ineligible for this QPI | 19 | 24 | 40 | 166 | 249 |
| Numerator | 1 | 1 | 0 | 7 | 9 |
| Not Recorded for Numerator | 0 | 0 | 0 | 0 | 0 |
| Denominator | 1 | 1 | 1 | 9 | 12 |
| Not Recorded for Exclusions | 0 | 0 | 0 | 0 | 0 |
| Not Recorded for Denominator | 0 | 0 | 0 | 0 | 0 |
| % Performance | 100.0% | 100.0% | 0.0% | 77.8% | 75.0% |

100% 90% 80% 70% Performance against QPI 60% 50% 40% 30% 20% 10% 0% Borders D&G Fife Lothian SCAN 2021/22 100.0% 100.0% 77.8% 75.0% 0.0% Target 75% 75% 75% 75% 75%

QPI 15: PD-L1 Combined Proportion Score (CPS) for Decision Making
Head and Neck Cancer 2021/22

KEY CATEGORIES

Table 1: Gender

| Total Patients | Diagnosed | M | ale | Fem | 35.0% 50.0% | | | | |
|-----------------------|-----------|-----|---------|-----|----------------|--|--|--|--|
| Borders | 20 | 13 | 65.0% | 7 | 35.0% | | | | |
| D&G | 38 | 19 | 50.0% | 19 | 50.0% | | | | |
| Fife | 64 | 42 | 65.6.0% | 22 | 34.3% | | | | |
| Lothian | 175 | 123 | 70.3% | 52 | 29.7% | | | | |
| SCAN | 297 | 197 | 100.0% | 100 | 100.0% | | | | |

Table 2: Age at Diagnosis

| Age | .90 | Borders | | D&G | | Fife | L | othian | | SCAN |
|-------|-----|---------|----|--------|----|--------|-----|--------|-----|--------|
| <45 | 1 | 5.0% | 1 | 2.63% | 4 | 6.3% | 9 | 5.1% | 15 | 5.1% |
| 45-49 | 1 | 5.0% | 1 | 2.63% | 6 | 9.38% | 5 | 2.9% | 13 | 4.4% |
| 50-54 | 1 | 5.0% | 4 | 10.5% | 5 | 7.8% | 13 | 7.4% | 23 | 7.7% |
| 55-59 | 2 | 10.0% | 7 | 18.4% | 9 | 14.1% | 23 | 13.1% | 41 | 13.8% |
| 60-64 | 3 | 15.0% | 6 | 15.8% | 6 | 9.4% | 25 | 14.3% | 40 | 13.5% |
| 65-69 | 3 | 15.0% | 7 | 18.4% | 13 | 20.3% | 33 | 18.9% | 56 | 18.9% |
| 70-74 | 4 | 20.0% | 4 | 10.5% | 10 | 15.6% | 26 | 14.9% | 44 | 14.8% |
| 75-79 | 2 | 10.0% | 2 | 5.3% | 8 | 12.5% | 22 | 12.6% | 34 | 11.5% |
| 80-84 | 2 | 10.0% | 4 | 10.5% | 1 | 1.6% | 11 | 6.3% | 18 | 6.1% |
| 85+ | 1 | 5.0% | 2 | 5.3% | 2 | 3.1% | 8 | 4.6% | 13 | 4.4% |
| Total | 20 | 100.0% | 38 | 100.0% | 64 | 100.0% | 175 | 100.0% | 297 | 100.0% |

Table 3: Tumour Site

N=All patients diagnosed

| Site of Tumour | В | orders | | D&G | | Fife | L | othian | S | CAN |
|---------------------------|----|--------|----|--------|----|--------|-----|--------|-----|--------|
| Larynx | 1 | 5.0% | 8 | 21.1% | 15 | 23.4% | 39 | 22.3% | 63 | 21.1% |
| Oral Cavity | 5 | 25.0% | 12 | 31.6% | 18 | 28.1% | 42 | 24.0% | 77 | 25.9% |
| Major Salivary Glands | 1 | 5.0% | 2 | 5.3% | 1 | 1.6% | 6 | 3.4% | 10 | 3.4% |
| Oropharynx | 10 | 50.0% | 12 | 31.6% | 20 | 31.3% | 62 | 35.4% | 104 | 35.0% |
| Nasopharynx | 1 | 5.0% | 0 | 0.0% | 1 | 1.6% | 1 | 0.6% | 3 | 1.0% |
| Hypopharynx | 1 | 5.0% | 3 | 7.9% | 5 | 7.8% | 18 | 10.3% | 27 | 9.1% |
| Nasal Cavity & Middle Ear | 0 | 0.0% | 0 | 0.0% | 1 | 1.6% | 5 | 2.9% | 6 | 2.0% |
| Accessory Sinuses | 0 | 0.0% | 0 | 0.0% | 2 | 3.1% | 0 | 0.0% | 2 | 0.7% |
| Bones | 0 | 0.0% | 0 | 0.0% | 1 | 1.6% | 0 | 0.0% | 1 | 0.3% |
| III Defined Sites | 1 | 5.0% | 1 | 2.6% | 0 | 0.0% | 2 | 1.2% | 4 | 1.4% |
| Total | 20 | 100.0% | 38 | 100.0% | 64 | 100.0% | 175 | 100.0% | 297 | 100.0% |

| QPI Attainment Summary Year 7 | Target% | Во | rders | | D& | G | | Fife | <u> </u> | | Lo | thian | | SC | AN | |
|------------------------------------------------------------------|---------|--------|----------|-------|--------|----------|-------|--------|----------|-------|--------|------------|-------|--------|------------|-------|
| QPI 1 Pathological Diagnosis of Head and Neck Cancer | 95 | N D | 16 16 | 100% | N D | 42 44 | 95.5% | N D | 57 59 | 96.6% | N D | 161 167 | 96.4% | N D | 276 286 | 96.5% |
| QPI 2(i) Imaging | 95 | N D | 16 16 | 100% | N D | 41 43 | 95.3% | N D | 56 58 | 96.6% | N D | 155 161 | 96.3% | N D | 268 278 | 96.4% |
| QPI 2(ii) Imaging | 95 | N D | 16 16 | 100% | N D | 40 41 | 97.6% | N D | 56 56 | 100% | N D | 150 150 | 100% | N D | 262 263 | 99.6% |
| QPI 3 Multi-disciplinary Team Meeting (MDT) | 95 | N D | 16 16 | 100% | N D | 42 44 | 95.5% | N D | 59 59 | 100% | N D | 166 167 | 99.4% | N D | 283 286 | 99.0% |
| QPI 4 Smoking Cessation | 95 | N D | 5 6 | 83.3% | N D | 8 13 | 61.5% | N D | 25 25 | 100% | N D | 42 57 | 73.7% | N D | 80 101 | 79.2% |
| QPI 5(i) Oral and Dental Rehabilitation Plan | 95 | N D | 12 14 | 85.7% | N D | 25 27 | 92.6% | N D | 35 40 | 87.5% | N D | 89 127 | 70.1% | N D | 161 208 | 77.4% |
| QPI 5(ii) Oral and Dental Rehabilitation Plan | 95 | N D | 9 11 | 81.8% | N D | 18 22 | 81.8% | N D | 28 32 | 87.5% | N D | 78 83 | 94.0% | N D | 133 148 | 89.9% |
| QPI 6 Nutritional Screening | 95 | N D | 16 16 | 100% | N D | 42 45 | 93.3% | N D | 49 60 | 81.7% | N D | 163 175 | 93.1% | N D | 270 296 | 91.2% |
| QPI 7 Specialist Speech and Language Therapist Access | 90 | N D | 1 12 | 8.3% | N D | 22 23 | 95.7% | N D | 25 31 | 80.6% | N D | 74 96 | 77.1% | N D | 122 162 | 75.3% |
| QPI 8 Surgical Margins - presented by hospital of surgery | <10 | N D | 0 0 | N/A | N D | 0 0 | N/A | N D | 0 | N/A | N D | 3 37 | 8.1% | N D | 3 37 | 8.1% |
| QPI 9 Intensity Modulated Radiotherapy (IMRT) | 95 | N D | 9 9 | 100% | N D | 15 15 | 100% | N D | 24 24 | 100% | N D | 70 70 | 100% | N D | 118 118 | 100% |
| QPI 10 Post Operative Chemoradiotherapy | 55 | N D | 0 0 | N/A | N D | 1 1 | 100% | N D | 1 3 | 33.3% | N D | 4 7 | 57.1% | N D | 6 11 | 54.5% |
| QPI 11a 30 Day Mortality (surgery) presented by hospital surgery | of <5 | N D | 0 | N/A | N D | 0 | N/A | N D | 0 | N/A | N D | 1 61 | 1.6% | N D | 1 61 | 1.6% |
| QPI 11a 90 Day Mortality (surgery) presented by hospital surgery | of <5 | N D | 0 | N/A | N D | 0 | N/A | N D | 0 | N/A | N D | 1 61 | 1.6% | N D | 1 61 | 1.6% |
| QPI 11b 30 Day Mortality (radiotherapy) | <5 | N D | 0 5 | 0.0% | N D | 1 3 | 33.3% | N D | 0 10 | 0.0% | N D | 0 29 | 0.0% | N D | 1 47 | 2.1% |

Not for wider dissemination – assessment risk of disclosure of sensitive personal information not yet undertaken

| QPI Attainment Summary Year 7 Tar | Target% | | rders | D&G | | Fife |) | | Lo | thian | | SCAN | | | | |
|----------------------------------------------------------------|---------|-----------|-------|-------|-------|------|---------|-------|----|-------|-------|------|------------|---|-----|--------|
| QPI 11b 90 Day Mortality (radiotherapy) | <5 | N | 0 | 0.0% | Ν | 1 | 33.3% | N | 0 | 0.0% | N | 2 | 6.9% | N | 3 | 6.5% |
| QFI 11b 90 Day Mortality (radiotrierapy) | 73 | D | 5 | 0.076 | D | 3 | 33.3 /0 | D | 9 | 0.076 | D | 29 | 0.976 | D | 46 | 0.5 /6 |
| QPI 11c 30 Day Mortality (chemoradiotherapy) | <5 | N | 0 | 0.0% | Ν | 0 | 0.0% | N | 0 | 0.0% | N | 0 | 0.0% | N | 0 | 0.0% |
| QFI 11C 30 Day Mortality (Chemoradiotherapy) | 73 | D 4 0.078 | D | 12 | 0.0 % | D | 14 | 0.0 % | D | 29 | 0.0 % | D | D 59 0.078 | | | |
| QPI 11c 90 Day Mortality (chemoradiotherapy) | <5 | N | 0 | 0.0% | Ν | 0 | 0.0% | N | 0 | 0.0% | N | 0 | 0.0% | N | 0 | 0.0% |
| QFI 11C 90 Day Mortality (Chemoradiotherapy) | 73 | D | 4 | 0.076 | D | 12 | 0.076 | D | 14 | 0.076 | D | 29 | 0.076 | D | 59 | 0.076 |
| Clinical Trial QPI NB: N = patients consented to Trials and on | 15 | N | 8 | 38.1% | Ν | 3 | 8.1% | N | 10 | 14.9% | N | 42 | 21.0% | N | 63 | 19.3% |
| SCRN database, D = 5 year average Cancer Registry Data | 15 | D | 21 | 30.1% | D | 37 | 0.1% | D | 67 | 14.9% | D | 200 | 21.070 | D | 327 | 19.5% |

N = Numerator, D = Denominator, % = % Performance.

| QPI Attainment Summary Years 4-6 | | | I | Borders | \$ | | D&G | | | Fife | | | Lothian | 1 | | SCAN | |
|--------------------------------------------------|-----------|-----|-------|---------|-------|-------|-------|-------|-------|-------|-------|-------|---------|-------|-------|-------|-------|
| Target % | | | Yr4 | Yr5 | Yr6 | Yr4 | Yr5 | Yr6 | Yr4 | Yr5 | Yr6 | Yr4 | Yr5 | Yr6 | Yr4 | Yr5 | Yr6 |
| QPI 1: Pathological Diagnosis of Head and Cancer | Neck | 95 | 100.0 | 100.0 | 90.0 | 95.8 | 100.0 | 100.0 | 100.0 | 100.0 | 96.2 | 97.5 | 100.0 | 95.7 | 98.2 | 100.0 | 95.9 |
| QPI 2(i) : Imaging | | 95 | 100.0 | 100.0 | 94.7 | 79.2 | 96.7 | 96.9 | 94.5 | 98.6 | 96.2 | 98.1 | 100.0 | 96.1 | 95.5 | 99.3 | 96.1 |
| QPI 2(ii) : Imaging | | 95 | | 100.0 | 100.0 | | 86.2 | 96.8 | | 100.0 | 98.0 | | 95.1 | 91.7 | | 95.7 | 94.2 |
| QPI 3: Multi-disciplinary Team Meeting (MDT) | | 95 | 100.0 | 100.0 | 100.0 | 91.7 | 100.0 | 96.9 | 97.3 | 100.0 | 98.1 | 98.8 | 100.0 | 99.4 | 97.8 | 100.0 | 98.9 |
| QPI 4: Smoking Cessation | | 95 | | 66.7 | 83.3 | | 60.0 | 85.7 | | 76.0 | 100.0 | | 47.7 | 81.8 | | 54.8 | 77.5 |
| QPI 5(i): Oral and Dental Rehabilitation Pla | an | 95 | | 100.0 | 86.7 | | 100.0 | 86.7 | | 61.8 | 87.5 | | 99.3 | 76.4 | | 90.3 | 81.3 |
| QPI 5(ii): Oral and Dental Rehabilitation PI | an | 95 | | 100.0 | 100.0 | | 90.9 | 100.0 | | 100.0 | 86.4 | | 89.5 | 92.9 | | 92.2 | 89.1 |
| QPI 6 : Nutritional Screening | | 95 | 81.3 | 78.6 | 95.0 | 16.7 | 67.7 | 75.8 | 71.2 | 86.5 | 80.0 | 80.8 | 87.5 | 94.1 | 73.0 | 84.2 | 89.2 |
| QPI 7 : Specialist Speech and Language T Access | herapist | 90 | 40.0 | 10.0 | 0.0 | 58.8 | 56.3 | 85.7 | 9.4 | 10.6 | 32.4 | 76.2 | 81.6 | 66.7 | 55.6 | 57.8 | 57.8 |
| QPI 8 : Surgical Margins by Hospital of Sur | gery | <10 | N/A | N/A | N/A | N/A | 0.0 | 0.0 | N/A | N/A | 0.0 | 5.3 | 4.9 | 17.2 | 5.3 | 4.8 | 15.6 |
| QPI 9 : Intensity Modulated Radiotherapy (| IMRT) | 95 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| QPI 10 : Post Operative Chemoradiotherap | у | 55 | N/A | N/A | 100.0 | 0.0 | 0.0 | 0.0 | 25.0 | 0.0 | 33.3 | 33.3 | 50.0 | 18.2 | 30.0 | 33.3 | 22.2 |
| QPI 11a: Mortality following surgery | 30 day | <5 | N/A | N/A | N/A | 0.0 | 0.0 | 0.0 | N/A | N/A | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| (presented by Board of surgery) | 90 day | <5 | N/A | N/A | N/A | 0.0 | 0.0 | 0.0 | N/A | N/A | 0.0 | 3.2 | 0.0 | 3.2 | 3.2 | 0.0 | 3.1 |
| ODI 44h Martalitu fallawina Dadiatharany | 30 day | <5 | 0.0 | 0.0 | 0.0 | 0.0 | N/A | 0.0 | 0.0 | 0.0 | 0.0 | 6.3 | 6.3 | 4.2 | 3.6 | 4.2 | 2.5 |
| QPI 11b: Mortality following Radiotherapy 90 day | | <5 | 0.0 | 0.0 | N/A | 0.0 | N/A | 0.0 | 0.0 | 0.0 | 0.0 | 6.3 | 6.3 | 4.5 | 3.6 | 4.3 | 2.9 |
| QPI 11c: Mortality following | 30 day | <5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.7 | 0.0 | 0.0 | 1.1 | 0.0 |
| Chemoradiotherapy | 90 day | <5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 | 0.0 | 0.0 | 2.3 | 0.0 |
| QPI 12: Clinical Trials | | 15 | 16.7 | 5.3 | 26.3 | 0.0 | 5.6 | 20.0 | 4.6 | 4.5 | 18.8 | 6.3 | 11.9 | 19.3 | 5.8 | 9.3 | 19.7 |

Not for wider dissemination – assessment risk of disclosure of sensitive personal information not yet undertaken

N = Numerator, D = Denominator, % = % Performance. QPIs 2 (ii), 4 and 5 were not reported in Year 4 following formal review, as additional data items were required